International consensus guidance for management of myasthenia gravis: Executive summary.
Neurology
; 87(4): 419-25, 2016 Jul 26.
Article
en En
| MEDLINE
| ID: mdl-27358333
ABSTRACT
OBJECTIVE:
To develop formal consensus-based guidance for the management of myasthenia gravis (MG).METHODS:
In October 2013, the Myasthenia Gravis Foundation of America appointed a Task Force to develop treatment guidance for MG, and a panel of 15 international experts was convened. The RAND/UCLA appropriateness methodology was used to develop consensus guidance statements. Definitions were developed for goals of treatment, minimal manifestations, remission, ocular MG, impending crisis, crisis, and refractory MG. An in-person panel meeting then determined 7 treatment topics to be addressed. Initial guidance statements were developed from literature summaries. Three rounds of anonymous e-mail votes were used to attain consensus on guidance statements modified on the basis of panel input.RESULTS:
Guidance statements were developed for symptomatic and immunosuppressive treatments, IV immunoglobulin and plasma exchange, management of impending and manifest myasthenic crisis, thymectomy, juvenile MG, MG associated with antibodies to muscle-specific tyrosine kinase, and MG in pregnancy.CONCLUSION:
This is an international formal consensus of MG experts intended to be a guide for clinicians caring for patients with MG worldwide.
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Miastenia Gravis
Tipo de estudio:
Guideline
Límite:
Adult
/
Child
/
Female
/
Humans
/
Pregnancy
Idioma:
En
Revista:
Neurology
Año:
2016
Tipo del documento:
Article